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1 Zusammenfassung
Rund 50% der von Menschen abstammende Tumoren besitzen eine mutierte Form des
TP53 Gens das für den TP53 Tumorsupressor kodiert[1]. Seit der Entdeckung dieses
"Wächter des Genoms" suchen sowohl pharmazeutische als auch akademische Labo-
ratorien nach gezielte Therapien um Tumoren mit einer defekten Kopie des P53 zu
beseitigen[2]. So viel versprechend dieser Strategie sein mag, bleiben der restlichen 50%
der Tumoren die einen Wildtyp TP53 besitzen davon unbetroﬀen.
Viele der in den p53 Apoptosesignalweg verwickelte Gene wurden durch funktionelle
zelluläre genetische Screens gefunden[3, 4, 5]. Die Meisten dieser Screens basieren auf
einen ähnlichen Prinzip, nämlich durch Hemmung eines p53 aktivierenden Genes, das
p53 Signalweges auszuschalten und Zellen in besitzt eines Kandidatengenes aufgrund ihrer
"Unsterblichkeit" zu isolieren. Auch wenn die gewonnen Einblicke in der apoptotische
Signalweg viele neue Erkenntnisse gebracht haben, hielt sich die klinische Relevanz von
den gefundenen Gene in Frage. Viel sinnvoller dagegen ist es solche Gene zu finden die
bei Inhibierung, eine p53 aktivierende Wirkung zeigen um dadurch Zellen dazu zwingen
in Apoptose zu gehen oder den Zellzyklus zu arretieren. Dies wurde bereits bereits bei
den chemischen Hemmung des HDM2 Gens durch Nutlin-3 gezeigt[6, 7].
Während meiner 12-monatige Diplomarbeit, begab ich mich einen "Loss-of-Function"
genetischen Screen zu entwickeln um weitere Inhibitoren der p53-Signalweges zu finden
mit der Idee, neue Angriﬀspunkte für Medikamente für die Krebstherapie zu identifizieren.
Meinen Auftrag war ein Selektionssystem zu testen wodurch Zelllzyklus arretierte Zellen
gegenüber sich teilende Zellen spezifisch ausgesucht werden sollten. Der Screen besteht in
Grunde aus vier spezifische Schritte: Als erstes wird einer p53 Wildtyp, immortalisierte
Zelllinie mit einer shRNA Bibliothek bestehend aus 24.000 retrovirale Vektoren gegen
9.000 menschliche Gene infiziert. Die Zellen werden dann im zweiten Schritt einer Be-
handlung unterzogen wodurch sich Teilende spezifisch getötet werden. Dies wird erzielt
durch Zugabe vom synthetischen nukleosid Bromodeoxyuridin (BrdU), dass während der
S-Phase des Zellzyklus von der Polymerase in den Genom statt Thymidin inkorpori-
ert wird. Die Zellen werden anschliessend mit der Hoechst #33158 Farbstoﬀ behandelt
und nach einer kurze Inkubationszeit mit UVa licht bestrahlt und dadurch werden DNS
Doppelstrandbrüche verursacht[8, 9, 10]. Zellen dessen Zellzyklus arretiert wurde durch
die Wirkung eines shRNAs werden von der Doppelstrandbrüche verschont, die Selektion
dieser Zellen wird im dritten "Auferstehungsschritt" ermöglicht. Nun werden überlebende
Zellen mit einem lentiviral exprimierten Large T Antigens infiziert mit der Erwartung
die Eﬀekte des shRNAs zu übertrumpfen und die Zellen somit zu stimulieren wieder in
Zyklus zu gehen und kolonien bilden. Genomisches DNA wird aus den Kolonien isoliert
und der shRNA vektor kann durch PCR identifiziert werden.
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2 Aim
In humans, roughly 50% of tumours possess a mutated form of the TP53 gene which
encodes the TP53 tumour suppressor[1]. Thus, since the discovery of this "Guardian
of the Genome", both pharmaceutical and academic research laboratories have been
thoroughly looking for ways to target tumours with defective P53[2]. However, there
is still the other 50% of tumours which have a wild type TP53.
Various functional genetic screens have identified genes that suppress p53 mediated
cell cycle arrest or apoptosis[3, 4, 5]. Although important for our understanding of the
mechanisms of action of these pathways, the therapeutic value of these findings is limited.
Instead it would be preferable to find genes that activate p53 when inhibited. As has
been shown with the small molecule Nutlin-3, inactivation HDM2, an upstream negative
regulator of p53, can activate the p53 pathway and induce cell cycle arrest and apoptosis
in cellular models[6, 7]. During the 12 month period of my diploma thesis, I set out to
develop a loss-of-function screen to identify further inhibitors of the p53 molecule with
the idea of finding novel drug targets for cancer therapy.
In the past, these screens have been hampered by the inability to recover knock down
vectors from arrested cells. Thus, we propose a strategy to circumvent this problem
and will perform a genome-wide shRNA screen to identify inhibitors of the pRB/P53
signalling network. We will infect immortalised cells with the retroviral shRNA NKi
library (9,000 genes targeted) at a low MOI and then submit the cells to a treatment
that will kill all dividing cells. This is accomplished with the help of Bromodeoxyuridine
(BrdU), a synthetic nucleoside which is incorporated into the genome of a replicating cell
in substitution of a thymidine. Several studies have shown that double strand breaks can
be induced in BrdU labelled cells by a subsequent treatment with Hoechst dye #33158
and UVa light[8, 9, 10]. We postulate that the BrdU/Hoechst/UVa induced double strand
breaks will kill or arrest all dividing cells, whereas non-dividing cells which are arrested
by one of the shRNAs from the NKi library should not be aﬀected. All surviving arrested
cells will then be infected with a lentiviral vector containing the SV40 Large T antigen
under the control of a CMV promoter. Colonies are expected to form where the arrest
has been induced by a shRNA that targets an inhibitor of the p53/Rb pathway, since
both p53 and Rb proteins are inhibited by the large T protein. Genomic DNA from
colonies will then be isolated and the knockdown vector recovered by PCR. If the shRNA
recovered is proven to by relevant and novel, we will further study its function and role
in the pathway in cooperation with other labs of CeMM.
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3 Introduction
3.1 Cancer
The most read and trusted reference place on earth, Wikipedia.org defines cancerous
as opposed to benign tumours as being a "class of diseases in which a group of cells
display uncontrolled growth, invasion, and sometimes metastasis." As simple as it is,
this definition accurately summarises the three key events in cancer progression, eﬀective
targeting of a cancer at any of these events will thus be correlated with a good disease
prognosis. All three events are equally important and subject to extensive research, the
focus of my project was on finding a mechanism to halt the uncontrolled growth of cancer
cells.
Pathologically, cancer incidence correlates with age as our genomes and proteomes
are more prone to malignant aberrations the older we get. The International Agency for
Research on Cancer estimated that for the year 2008 there were worldwide 7.6 million
deaths from cancer[11]. Due to our ever improving living standards, it is very plausible
that our life expectancies as a species will increase in the foreseeable future[12]. To put
this in context, until the relatively recent discovery of antibiotics, millions of years of
evolution had fine tuned the human species to a life expectancy of a maximum of 40
years of age. Since the beginning of the 20th century there has been a huge rise in age
expectancy (Figure 1a). This trend could also be correlated with the increasing number
of cancer deaths worldwide (Figure 1b).
Figure 1: Correlation of age expectancy and cancer incidence. a) Since the beginning of the 20th
century there has been an exponential growth in the life expectancy, in part due to improving
hygienic standards and by the discovery of antibiotics. Adapted from [13].b) Projections from
the IARC estimate that four million more cancer cases will be diagnosed in 2020 as compared
to 2008.
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Biologically, cancer can be best understood if seen as the "escape" of a cell or group of
cells from its intrinsic function in the higher complexity of an organism to an individual
entity. This new entity possesses the qualities of an aggressive parasitic organism, in that
it will try its best to survive in some cases by diverting valuable energy resources from
the hosts body to feed its own needs, even if this eventually leads to the death of its
host. Inevitably a selective pressure is impinged upon both the cancer and the host and
both naturally evolve mechanisms that ensure survival. Thus every cell in a multicellular
organism has over the course of time evolved a wide variety of intrinsic safeguards that
protect the organism as a whole from such cancerous cells. However, as a replicating
entity, individual cells also possess a drive to reproduce. What from the multicellular
organisms’ point of view may seem as a failure might be a victory for the individual cell.
To understand the series of events leading to the uncontrolled growth of a cell it is
essential to first elucidate the intricate molecular pathways governing the progression of
the cells’ most ancient mechanism: the ability to reproduce. The key steps in this process
are governed by the cell cycle.
3.2 The cell cycle
Every single cell in the body is originally derived from a single cell generated during
fertilisation. The series of events that lead to cellular division is defined as the cell
cycle. Figure 2 is a schematic and simplified depiction of the cell cycle with its respective
checkpoints. Each new event in the cell cycle can only begin once the checkpoints of
the preceding steps have been cleared. At the center of most if not all cancers lies a
mis-regulation in the cell cycle.
Normally, cells in the body will divide and diﬀerentiate until the final state of the
given cell lineage is reached, after which the cell will be purposely stalled in one of the
cell cycle steps. This arrest is crucial in order to keep the homeostasis of cells in the body,
however it is also an essential defence mechanism against cells attaining cancer-inducing
mutations. The genetic information within the cell remains inactive, thus it is within
reason to theorise that even after full diﬀerentiation every single cell retains the potential
ability to divide mitotically. Indeed, the recent work of Yamanaka has shown that a
pluripotent state can be artificially induced in fully diﬀerentiated fibroblast cells [15, 16].
A myriad of mechanisms are in place that meticulously regulate cell cycle progression,
and there are two seemingly central proteins on which many of the checkpoint signals
impinge: P53 and Rb.
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3.2.1 p53
Figure 2: Schematic depiction of the cell cycle.
Each phase of the cell cycle is rigorously con-
trolled for completion. When an aberrant event
is detected the cell cycle will stall until the errors
are corrected or until a bypass signal is received.
Modified from Alberts Molecular Biology of the
Cell[14].
The TP53 gene itself is mutated in roughly
50% of tumours which make it the most
frequently inactivated protein in human
tumours analysed. Furthermore, an ever
growing number of post-translational miss-
regulations which inactivate the wild-type
p53 gene product, leave no doubt that the
p53 protein is worthy of its "Guardian of
the Genome" nickname[17]. It is specif-
ically the post-translational regulation of
the p53 pathway, which has recently gained
the attention of the scientific community
after several high profile studies showed
that the activation of p53 in tumours can
be readily achieved by inhibition of p53 in-
hibitors. The central inhibitor of the p53
protein is the MDM2 protein[18]. MDM2
binds to p53 and inhibits its function by
(1) inhibiting the transactivation domain of the p53 protein, (2)promoting the proteaso-
mal degradation of p53 through its E3 ubiquitin ligase function, and (3)through nuclear
export of p53 (Figure diagram of p53-MDM2 interactions). Any form of p53 inhibition
has the potential to promote cell cycle progression making MDM2 a very potent onco-
gene. Interestingly Yamanaka’s group recently showed that a reduction in the p53 levels
increases the eﬃciency of IPS cell generation both in human and in mouse cells[19].
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Figure 3: Regulation of p53 activity by MDM2. The MDM2 protein plays a central role in the
regulation of the p53 tumour suppressor.Adapted from Chene 2003[2].
3.2.2 RB
The second central protein in the regulation of cell cycle progression, is the retinoblastoma
(RB) protein. Important downstream eﬀectors of RB are the E2F family of genes. These
genes were initially associated with the regulation of the G1/S-phase transition, more re-
cent studies have implicated these genes in apoptosis, diﬀerentiation and DNA-Damage
signalling pathways[20]. RB possesses at least 16 CDK phosphorylation sites, and its
activation status depends on its phosphorylation state [21]. As the cell cycle progresses
RB is phosphorylated by members of the cyclin dependant kinases family (CDKs), the
hypophosphorylated state of RB is restored by pyrophosphatase 1 (PP1) after DNA repli-
cation has been completed. RB belongs to a family of structurally and functionally related
proteins which include p107 and p130, which functions however are diﬀerent depending
on the cellular context [22]. A striking diﬀerence for example is that the RB gene, in con-
trast to p107 and p130, is frequently mutated in cancerous tissue, and loss of RB function
has been shown to be involved from cancer initiation to cancer progression[23]. As with
p53, post-translational modifications of the RB gene add to malignant miss-regulations
in the pRb pathway. For example, over-expression of Cyclin-D or CDK4 kinases will lead
to enhanced Rb phosphorylation and thus cell cycle progression[24].
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3.2.3 Links between p53 and Rb
Although structurally unrelated, the overlap between p53 and RB functions impossibly
escapes attention. The regulation of these two pathways is extensive and diverse but
some intriguing convergences of the pathways do occur. I will shortly mention two of
these examples in the following paragraphs.
Figure 4: Links between p53 and Rb pathways. a) Oncogenic signals can induce the ARF tumour
suppressor which in turns inhibits MDM2 thus hindering the inhibition of p53.b) Similarly, the
INK4a/b tumour suppressor inhibits the CDK4-Cyclin D which in turn cannot inactivate p21
hindering the hyperphosphorylation of RB. is not complex. Adapted from [25].c) Schematic
depiction of the Large T antigen. Adapted from [26].
3.2.3.1 INK4a ARF locus First, an important regulator of these two pathways is
the p16INK4a/p14ARF locus which encodes for three critical tumour suppressors INK4a
INK4b and ARF. The two INK4 sequences are arranged in tandem, but are separated by
an exon designated 1β which is transcribed incorporating exons 2 and 3 from p16INK4a,
albeit in a diﬀerent reading frame thus the name Alternative Reading Frame (ARF) pro-
tein. ARF has no amino acid sequence or biochemical function homology to p16INK4a and
the evolution of the gene locus remains a mystery. The gene products of p16/15INK4a/b
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work by inhibiting CDK4 and CDK6 which thus cannot phosphorylate Rb and the cell
cycle is arrested in the G0/G1 phase (Figure 4a), the ARF protein binds to MDM2 in-
hibiting its ubiquitin ligase activity thus stabilising the p53 protein (Figure 4b)[25, 27].
One would expect the expression patterns of the p16INK4a and p14ARF gene products
to be similar, however extensive studies have not been able to show this in any cellular
model [25].
3.2.3.2 SV40 LargeT antigen The second example of convergence between the
p53 and Rb pathways, is an extrinsic rather than an intrinsic one. Viruses have been
perfecting the art of tinkering with the cellular replication machinery for millions of years.
Many DNA tumour viruses have developed special viral proteins to bind and inactivate
Rb or p53 such as the E7/E6 proteins from the human papiloma virus (HPV) family
or the Large T antigen from the simian vacuolating virus family (SV40). In the case of
the SV40 virus, its large T (LT)-Antigen protein is a single multifaceted protein which
binds and inhibits both p53 and Rb thus stimulating early S-Phase entry and its own
replication. In addition, LT interacts with a variety of other cell cycle related proteins,
like MDM2, p300/CBP, CUL7, BUB1, TEF-1, NBS1, FBW7, as well as HSC70(Figure
4c)[28].
3.2.4 The therapeutic potential of targeting p53 or RB post-translational
inactivators
The focus of several recent high impact publications has been the activation of either the
Rb or the p53 pathways to activate the cells natural cancer defence mechanism. These
studies have focused on finding inhibitors of p53/Rb inhibitors. Surprisingly, although
activation of these pathways in cancerous cells leads to cell death and apoptosis, no
adverse eﬀects have been shown in normal cells.
For the p53 protein, scientists have succeeded in creating small chemical inhibitors
which disrupt the MDM2-p53 interaction[6, 29, 30]. The most promising chemical in-
hibitor candidates are Nutlin3a and M-219. P53 wild type cancer cells treated with any
of these two compound show up-regulation of p53 and its putative target p21, and induce
p53 dependent cell death by apoptosis. Both compounds show achieve this with a very
high aﬃnity.
As of today no such central inhibitor for Rb has been found, as HDM2 is for p53. In-
vestigation into disrupting the interaction of several of the cell cycle kinases has yielded
only moderate results thus far[31]. The Raf-1 kinase was found to bind and phosphorylate
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Rb very early in the cell cycle, promoting its activation [32]. Davis and colleagues cor-
rectly hypothesised, that a small chemical inhibitor disrupting the formation of the Raf-1
Rb interaction would inhibit an activated Rb thus prompting cells to go either into cell
cycle arrest or apoptosis. Indeed, cells treated with the specific Raf-1 inhibitor RRD-251
showed precisely this phenotype and nude mice bearing human cancer xenografts showed
a retraction of the tumour at physiologically relevant concentrations[33, 34].
3.3 Functional loss-of-function genetic screens in mammalian cells
Functional genetic screens in model organisms such as yeast, fruit-fly and worms have pro-
vided a wealth of information about components of the mammalian signalling system[35].
However, there are limitations to translating the results of these screens to human be-
ings. The use of mammalian cells to study cancer development had until recently been
hampered by the lack of eﬀective genetic tools. However, the number of tools that have
been developed has increased dramatically in the last years. The fastest growing of which
without a doubt has been the discovery and further implementation of small interfering
RNAs.
3.3.1 RNAi knockdown libraries
Loss of function genetic screens aim to identify gene functions through inactivation of a
gene or its corresponding mRNA. Various technologies exist to suppress genes in mam-
malian cells among which RNA interference has proven to be the most eﬀective and
reproducible. RNAi is an ancient defence mechanism to protect cells from foreign inva-
sion agents such as transposons and viruses. Double-stranded RNAs produced by these
agents are processed into short double-stranded RNAs by DICER, which in turn signal
the RNA-induced silencing complex (RISC) which in turn degrades homologous mRNA
molecules[36]. By making artificial sequences targeting an ORF of a target gene, scientists
have been able to pointedly silence an ever growing number of genes[35] . However, this
same mechanism makes the use of RNAi in mammalian cells a problematic issue since
the introduction of long double-stranded RNA molecules leads to nonspecific toxicity
mediated by the γ-interferon pathway[37].
Generally, two ways have been developed to overcome this toxicity. First, the tran-
sient transfection of 21-23 base pair double stranded siRNAs which directly recruit the
mammalian RISC without eliciting γ-interferon response [38]. Some hurdles however are
the transient nature of these constructs, the diﬃculty to transfect i.e. primary cells,
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and the high cost of synthesising siRNAs. Vector systems that mediate stable pro-
duction of siRNA-like molecules in mammalian cells overcome the problems of siRNA
transfections[39]. Most of these vectors use RNA-polymerase III promoters to direct the
synthesis of short hairpin RNA (shRNA), consisting of a double-stranded stem of 19-29
base pairs targeting the mRNA to be suppressed connected by a loop of 6-9 bases. These
molecules are processed intracellularly into siRNA-like molecules. Stable integration of
these expression cassettes into the host genome can be achieved through retroviral or
lentiviral delivery vectors[40].
3.3.1.1 The NKI RNAi knockdown Library The RNAi library used in my project,
was produced through high-throughput cloning of short-hairpin-encoding DNA oligonu-
cleotides into a retroviral vector (pRetroSuper) with the RNA-polymerase III promoter
at the Netherlands Cancer Institute (NKI for its abbreviation in Dutch)[5]. It consists of
23,742 knockdown vectors targeting 7,914 human genes. Each mRNA transcript is tar-
geted by three sequence independent vectors, thus increasing the likelihood of functional
inhibition of gene expression. A further important characteristic of shRNA libraries is the
ability to isolate and identify the individual hairpins after genome integration and siRNA
expression. Accordingly, all the 19-meres in the NKi RNAi library are flanked by com-
mon primer sites within the LTRs. These allow for an easy recovery through conventional
genomic DNA PCR, the 19-mer itself then serves as a unique barcode identifier.
3.3.2 Previous screens: Finding genes that induce senescence
Previous screens have focused on finding candidate genetic interactions that inactivate
the p53/Rb proteins thus bringing cells back into cycle. One of the very first loss of
function screens in mammalian cells was performed by the group of Rene Bernards and
is outlined in Figure 5 [5]. For their approach they generated a hTERT immortalised
primary human foreskin fibroblast cell line containing a temperature sensitive allele of
the SV40-large T antigen (from know on BJ-TERT-tsLT cells). Culturing the cells at
32◦C the active Large T permits cells to grow, switching the temperature to 39◦C causes
synchronous p53 dependent cell cycle arrest and apoptosis. The Bernards’ group infected
the BJ-TERT-tsLT cells with the NKi library and screened for cells that would grow at
39◦C implying the escape of senescence in a p53 Rb dependent manner.
Similar to the approach by Bernards, a second screen performed by the group of David
Bernard, focused on shRNAs that would allow candidate cells to escape the senescent
state [3]. In their setup, they infected human lung fibroblast cells (WI38) known to
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undergo senescence after 50 ± 10 cycles, with a shRNA library and screened for cells
that escaped senescence.
Figure 5: Outline of mammalian RNAi screen
to identify inducers of cell cycle arrest. BJ-
TERT-tsLT cells will grow at 32◦C and ar-
rest at 39◦C. By infecting actively dividing cells
with the shRNA and then switching to the non-
permissive temperature, some cells will escape
the arrest and grow into clonal colonies. The
knockdown eliciting this phenotype can then be
easily recovered through PCR. Modified from [5]
Although these screens provide insight
into key pathways involved in the cell cy-
cle, the resulting information is of limited
therapeutic value. As mentioned before,
the desirable eﬀect to elicit in cancer bi-
ology is to stop the erratic cell divisions
by either arresting the cells at some point
in the cell cycle or by specifically killing
the cells. In order for the candidate genes
identified by both the Bernards and the
Bernard groups to elicit such a response,
the genes or gene products must be acti-
vated which is not a trivial matter.
3.3.3 Our approach: Finding Genes
that evade senescence
As of today most drugs are designed to dis-
rupt the function of a gene or gene prod-
uct. Thus, of a much higher therapeutic value would be to identify genes that confer a
cell the ability to bypass the inherent cellular safeguard mechanisms, and to inhibit the
gene’s function. The identification of such a gene, if proven to be involved in a central
regulatory pathway, could eventually lead to a specific drug target. On this account, my
master thesis project focused on developing a screening method that would single out
genes that elicit a senescent phenotype in cells.
The novelty of our approach lies with the ability to screen for genetic interactions that
activate the cells intrinsic defence mechanism by activating either p53 or Rb. I attempted
to accomplish this by developing a four-step screening technology (Fig. 6). The four
steps of our approach are:
1) The knockdown of genes with a shRNA library.
2) The systematic killing of all cells which are still dividing.
3) Stimulating cells which survived the previous step to re-cycle.
4) Identifying and confirming the shRNA responsible.
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Figure 6: Schematic diagram of the four-step ap-
proach. Cells infected with the NKi retroviral li-
brary are submitted to the BrdU/hoechst/UVa
treatment which will kill all dividing cells. Re-
maining cells are then infected with a lentiviral
vector expressing the SV40 Large T antigen un-
der the CMV constitutive promoter. Cells which
are rescued from senescence by the Large T anti-
gen will divide until colonies are formed. The
genomic DNA of the individual colonies is anal-
ysed and the hairpin sequence is recovered by
PCR.
3.3.3.1 Knockdown The first step
consists of knocking down a wide array of
genes by infecting the desired cells with the
NKi shRNA knockdown library described
in 3.3.1.1. We hypothesise that a senescent
phenotype will be induced by some of the
roughly 8,000 genes silenced by the library.
3.3.3.2 Killing After giving an appro-
priate time for the infected cells to prop-
erly express the introduced shRNA and ac-
quire the desired senescent phenotype, the
cells will be subjected to a treatment that
selectively kills cells that are still under-
going the full cell cycle. We attempt to
do this by implementing a previously de-
scribed method to induce double strand
DNA breaks in cells treated with a com-
bination of 5-bromo-2’-deoxyurine (BrdU)
the Hoechst 33 258 dye and Ultraviolet A
light. The exact protocol can be found in
the Materials and Methods section and in:
[41, 8, 42, 10] . The method is based upon
the finding by Limoli and collegues, that
cells which have incorporated the thymi-
dine analogue BrdU into their genomes
during S-phase were more sensitive to UVa
radiation than cells which had not [42]. Further treatment of these cells with the Hoechst
33258 dye enhances the eﬀect to the extent where almost 100% of cells with incorporated
BrdU are selectively killed. We hypothesised that if we could accomplish a similar eﬃcacy
in killing dividing cells, only cells arrested by an shRNA from the previous step would
survive.
3.3.3.3 Re-cycle As was demonstrated by the BJ-hTERT-LTts cell line, cells can be
forced into cycle in a p53 dependent manner with the help of the SV40 Large T antigen[5].
Thus we hypothesised that by introducing an active form of the Large T antigen into
cells which have been arrested, we could overcome the arrest and once again the cells
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would start dividing. Our hypothesise is however based on two presumptions, first of all,
that the cells have gone into cell cycle arrest due to the silencing of an essential gene in
the p53 or Rb pathways. Secondly, the eﬀect of the Large T mediated inactivation of p53
or Rb must be dominant to the activation of the pathway by the hairpin. In cells where
both premises are fulfilled, the cell cycle will be kick started again and individual clonal
colonies should grow out.
3.3.3.4 Identify and confirm The clonal colonies are cultured until a suﬃcient
cellular mass is achieved, after which genomic DNA (gDNA) is isolated and using the
universal primer pairs common to every hairpin and the gDNA as a template, a PCR is
performed. The product of the PCR is then sequence analysed using the same primers
as for the amplification, with the help of the basic local alignment search tool (BLAST)
the 19-mer sequence is assigned to its target mRNA. After a successful identification, it
is crucial to confirm whether the senescent phenotype was indeed induced by the hairpin.
The confirmation step is explained in detail in the Results section.
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4 Results
4.1 Setting up the screen
As explained in the previous sections, the screening method consists of a four-step pro-
cedure. Although the technologies we intended to implement for our screen had been
previously published, this by no means implies that they will all work under every exper-
imenters hands or in all cell systems. Thus, the first months of my thesis were dedicated
to finding the optimal conditions for each of the four steps described in section 3.3.3. The
highest priority when performing a large scale study is to carefully choose which model
organism best suits the problem at hand. Our screening methods were conceived for use
in cell lines kept in culture. There are an enormous variety of available cell lines for
research purposes, thus as a first step it was essential to find the appropriate cell system
to study.
4.1.1 Cell lines
Independently of the original cell line’s source, it is absolutely necessary that the p53/Rb
proteins be wild-type for the Large T to be able to act. Furthermore, BrdU/Hoechst/UVa
treatment should eﬃciently kill more than 99% of cycling cells. In order to not spend
more time than needed in establishing the proper handling of a newly acquired cell line,
we decided to search among the available cell lines in our lab for an appropriate candidate.
The p53 Rb wild-type requirement on itself narrowed our search down to three candidate
cell lines: U2OS, MCF10a and IMR90 which are individually described in the Materials
and Methods section and depicted on Figure 7.
Figure 7: Cell lines proposed to perform the screen. Phase contrast microscopy photographs at
40x magnification of a human embryonic fibroblast IMR90 a), a human osteosarcoma cell line
U2OS b) and a non tumourigenic breast epithelial cell line MCF10a c). The three cell lines
were submitted to the diﬀerent steps in the process to assess their suitability for performing the
screen.
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4.1.2 NKi Library
Immediately after receiving the pRetroSuper NKi shRNA library from the Bernards lab,
I proceeded to package it into retroviral particles. Unfortunately, this turned not to be
so trivial as in 8 out of 19 attempts to produce functional viral particles, the NKi shRNA
library viral titre was either extremely low or non existent when tested on diﬀerent cell
lines(Figure 8a)). An aliquot of the library was submitted to both sequence verification
and restriction enzyme digest to confirm the identity (Figure 8b). The only unexpected
result was an unidentified but persistent (n=3) band at ∼6kb, which could either be due
to incomplete digestion of the plasmid or due to a plasmid contamination. Given that the
problems persisted we pursued to retransform the shRNA library into ultra-competent
E.Coli bacteria.
Figure 8: Low viral titre with the newly acquired NKi library. a) Crystal violet staining of U2OS
cells infected with three diﬀerent viral harvests (H1-H3) from the NKi library and the pRS-GFP
vectors. Staining was done after two days of puromycin selection. b) Agarose gel electrophoresis
pictures of the pRS-NKi and pRS-GFP vectors digested with the KPNI restriction enzyme.
4.1.3 BrdU/Hoechst/UVa
The method for killing dividing cells has previously been described[41, 8]. I attempted to
establish killing protocols for all three candidate cell lines. Concentrations were left the
same as had been described before, changing only the duration of the BrdU treatment.
For our screen, survival after BrdU/Hoechst/UVa treatment should be reduced to roughly
2-4 cells per well of a multi-well 6-well well or 6-12 colonies on a 100mm dish so as to
keep the background levels to a minimum.
First to test whether our experimental setup was correct, I attempted to replicate
the experiment by Burmer and Norwood in HeLA cells[41]. As reported, after only a
three day BrdU treatment, followed by Hoechst 33258 and UVa, 1-2 background colonies
of HeLA cells were observed (Figure 9a). Having established the proper killing protocol
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for HeLA cells, I proceeded to investigate whether similar results could be achieved in
IMR90, MCF10a and U2OS cells.
Figure 9: BrdU Hoechst UVa treatment eﬀec-
tively kills HeLA but not IMR90 cells. a) HeLa
cells treated with both BrdU and Hoechst suc-
cumbed after UVa irradiation 2 in comparison
to cells treated only with Hoechst 1 only with
BrdU 4. Non-treated cells are shown as a com-
parison 3. b) Same as in a) with IMR90 cells.
c) IMR90 cells plated at increasing densities and
treated with upper lane or without lower lane
BrdU at the indicated concentration, cells were
stained with crystal violet dye after 4 days in
culture.
4.1.3.1 IMR90 Being a primary fi-
broblast cell line, IMR90 cells have a
rather intact karyotype compared to im-
mortalised cell lines which can be quite
heterogenous even within a certain cul-
ture. Previously it had been shown in sev-
eral diﬀerent skin fibroblast cell lines and
specifically in IMR90 cell lines that a small
population of slowly growing cells were re-
sistant to the BrdU/Hoechst/UVa proto-
col probably due to low levels of BrdU
incorporation[41, 43, 44]. As a matter of
fact, after Hoechst 33258 and UVa irradi-
ation only a small percentage of cells ac-
tually died (Figure 9b) and furthermore,
IMR90 PD 14 cells treated with BrdU dis-
played a noticeable growth defect pheno-
type (Figure 9c). Therefore, the cell line
was deemed unsuitable.
4.1.3.2 MCF10a I next attempted
the killing protocol on the MCF10a cell
line[45]. These cells are not known to go
into a senescent state even after multiple
passages. In contrast to the IMR90 cells,
MCF10a cells treated with BrdU displayed
a normal growth phenotype (data not
shown), and indeed after Hoechst 33258
and UVa treatment, very few cells seemed to survive. However, cells that did survive
the treatment readily went into cycle forming >15 colonies per 100mm dish in a period of
2 weeks post treatment (Figure 10a). I hypothesise that the patch-like growth of MCF10a
cells might hamper cells closer to the center of a patch to divide possibly by contact inhi-
bition, and thus to properly incorporate BrdU (Figure 7c). Once the dividing cells which
lie on the outside of the patch have been killed, contact inhibition is abrogated and cells
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which had stopped cycling can start again.
4.1.3.3 U2OS As expected, the killing protocol worked seamlessly for the fast divid-
ing U2OS cell line. The slight disadvantage with using cell lines is that they have been
in culture for long periods (e.g U2OS since 1964) and there are doubts as to whether
there is a resemblance to primary cancer cells. The advantage being that finding a gene
that hinders such a sturdy cell line from growing could possibly prove extremely useful
in cancer research. After a 72 hour BrdU treatment, ≤0.1% of cells formed colonies 2
weeks post treatment (Figure 10b). This made the U2OS cells the only viable candidate
to perform a test screen.
Figure 10: BrdU killing protocol kills U2OS cells but not MCF10a. a) MCF10a cells treated for
diﬀerent time periods with BrdU display an increasing mortality rate which correlates with the
length of the treatment, however multiple colonies arise after the dishes are kept in culture for a
2 week period. b)U2OS cells treated only for three days with BrdU display none to two colonies
(data not shown) 2 week after UVa irradiation.
4.1.4 LargeT antigen
I encountered problems both producing viable virus and sequence verifying an existing
lentiviral pWPI SV40 Large T vector. Western blot analysis showed that in fact no Large
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T protein was being made by the aforementioned vector. A second retroviral vector
pBABE Large T did properly express the Large T antigen (Figure 11a). A retroviral
vector is of no use to introduce the LargeT antigen into non-dividing cells to reinitiate
S-Phase DNA synthesis. The options left are to either transfect the cells with the pBABE
vector, or to shuttle the coding sequence for the Large T antigen into a lentiviral vector.
Thus, we opted for shuttling the Large T coding sequence from the pBABE-hygro to a
pLKO.2-CMV-puro vector. The finished vector was sequence verified and expression of
the Large T antigen was confirmed by western blot analysis (Figure 11b).
Next it was important to determine whether Large T expression would reinitiate cell
cycle in arrested cells. IMR90 cells go into a senescent state after hRASV12 expression
in a p53/pRB dependant manner and this eﬀect can be countered by expression of the
SV40 Large T antigen[46, 47]. Thus we infected IMR90 cells with a lentivirus containing
the RASV12 protein under a CMV promoter and after the strong senescent phenotype
was observed in these cells, a subsequent infection with the plKO.2-CMV-LargeT virus
was done. Large T infected cells were observed to go back into cycle and started forming
colonies (Figure 11c) as opposed to non-infected cells, thereby confirming the functional
expression of the Large T antigen.
As opposed to the pRS-NKI library virus, all three candidate cell lines were readily
infected with the plKO.2-CMV-LargeT virus (data not shown).
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Figure 11: Creation of a functional lentiviral vector expressing the SV40 Large T antigen. a)
Large T antigen could not be detected from the pWPI-Large T vectors when transfected into
U2OS cells (lanes 1-3), the pBABE-Hygro Large T vector available did display a large T band
at the expected size (lane 5). Untransfected 293T cell lysate was used as a positive control
(lane 7) and untransfected U2OS cells were used as a negative control (lanes 3 and 6). b)
The Large T sequence was shuttled from the pBABE-Hygro vector into a pLKO.2-CMV-Puro
vector and U2OS cells were infected with the resulting virus. Two prominent bands at 97 and
45 kDa were detected for Large T and Small T respectively (lanes 1-2) untransfected 293T cells
(lane 3) and untransfected U2OS cells (lane 4) were used as a positive and negative controls
respectively. c) IMR90 transduced with a pLKO.2-CMV-kRASV12 expressing vector, and after
2 days infected with the newly created pLKO.2-CMV-LT vector went back into cycle (upper
pictures). IMR90 cells transduced first with the pLKO.2-CMV-LT vector and then with the
pLKO.2-CMV-kRASV12 vector did not go into cell cycle arrest and continued dividing (lower
pictures).
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4.2 Test screen in U2OS cells
After carefully considering the results from the previous section we came to the conclusion
that if we were to make a test run for the screen, it would be advisable to use the U2OS
cell line as a model. In summary, three important facts make this cell line an adequate
model to work with. First, the U2OS cell line is reportedly p53/RB wild-type (although
we did not test this assertion for our specific batch), second, high titre infections with
both our pRetroSuper and pLKO.2 vectors were achieved and third the BrdU killing
protocol killed most if not all dividing cells after only 72 hour treatment.
4.2.1 Layout and implementation of a test screen
The exact protocol followed is described in the Materials and Methods section 6.6. U2OS
cells were infected with both the NKi library virus and the pRS-GFP as a negative
control. Cells were then submitted to the BrDU killing protocol and after a recovery
period of 48 hours cells were infected with the pLKO.2-CMV-Large T lentivirus. At first,
surviving cell numbers were indistinguishable between the NKi and the GFP infected
U2OS cells. After a two week recovery period, two and three colonies were seen in each
of the pRS-GFP negative control cells infected with the Large T lentivirus, whereas only
one colony was observed in a control dish without Large T. This observation was in
contrast with an average of five colonies per 100mm dish observed in the NKi infected
U2OS cells (n=20 dishes. Total colonies collected = 100). Colonies were collected and
separated to individual wells on a 48-well plate, identification of the candidates through
genomic DNA isolation and subsequent PCR was done for each candidate as soon as
enough cell material was available. We reasoned that a confluent 6-well would be more
than suﬃcient for several tests, thus cells were carefully passaged from a 48-well to a
24-well to eventually a 6-well.
Table 1: Preliminary list of candidates which could be successfully sequence verified.
Gene Function
NUCKS1 (nuclear casein ki-
nase and cyclin-dependent ki-
nase substrate 1)
Contains a putative DNA binding domain; and serves as a CDK1
Substrate.[48, 49]
ATR (Ataxia telangiectasia
and Rad3 related)
ATR is needed for the activation of the S-phase checkpoint after UV
induced ICL (DNA inter-strand link)lesions. Cells with siRNA against
ATR will ignore lesions and go into cycle. [50, 51]
CRYM (Crystallin µ) CRYM expression is androgen regulated in prostate cancer. [52]
PIP5KIß
(phosphatidylinositol-4-
phosphate 5-kinase; type I;
beta)
Very large family. Diverse functions. [53]
LPXN (Leupaxin) Expressed in human prostate carcinomas (Pca). Knockdown reduces
migratory and invasive behaviour in PCa cells [54]
22
PSAP (Prosaposin) Stimulates p53 expression in Pcas and inhibits tumour metastasis.
[55]
FGFR3 (Fibroblast Growth
Factor Receptor 3)
Rhabdomyosarcoma cells expressing FGFR3 have tumour initiating
potential, and chemical inhibition of FGFR3 can induce apoptosis in
myelomas. [56, 57]
CRK (Chicken tumour virus
No.10 Regulator of Kinase)
Originally described as a viral oncoprotein CRK is downstream of
FGFR signalling.[58, 59]
CD68 afjkaef
BID (BH3 Interacting Domain
Death Agonist)
Over-expression of BID induces P53 independent apoptosis. BID lev-
els are regulated by p53, BID is downstream of p53. [60, 61, 62]
4.2.2 Preliminary candidates
Out of the 100 colonies originally collected 55 of the candidate colonies did not survive
after being passaged and transferred to individual wells. Nonetheless, surviving candi-
date colonies were collected, the individual genomic DNAs isolated and sequence verified
(Table 1). Once again, only 21 of the 45 genomic DNAs analysed seemed to contain a
19-mere insert, indicating to a rather high background level.
The candidates that could be sequence verified were then shuttled into a pRetroSu-
per vector for individual confirmation of the cell cycle arrest inducing phenotype. The
protocol followed was the same as with the test screen. No morphological changes were
observed after infection with any of the hairpins, however after BrdU selection, U2OS
cells infected with five hairpins seemed to undergo cell cycle arrest as assessed by mor-
phological changes of the cells through light microscopy(Figure 12). To test whether
infection with the Large T lentivirus would bring the cells back into cycle, I proceeded
to passage them to be able to do the infection in duplicate. Unfortunately, this resulted
in cell death of all the candidates.
Subsequent multiple attempts to reproduce this experiment were unsuccessful due to
technical reasons. Nonetheless I proceeded to evaluate the knockdown eﬃciency in order
to see that this was not just an oﬀ-target eﬀect.
4.2.2.1 RT-PCR and Western blot confirmation of knockdowns A common
problem encountered when working with shRNAs is that the desired phenotype is elicited
not by a biological eﬀect of the knockdown but by an oﬀ-target eﬀect of the hairpin.
The shRNA hairpins contained in the NKi library have neither been sequence verified
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Figure 12: shRNAs found to in-
duce a cell cycle arrest in U2OS
cells. U2OS cells infected with
retroviral vectors containing an
shRNA targeting the indicated
genes and submitted to a BrdU
Hoechst UVa treatment. Cells
infected with a pRS-GFP vec-
tor or with a vector which could
not be identified from the screen
all died after treatment. A total
of 17 vectors were successfully
shuttled from the genomic DNA
of U2OS cells from the screen
into a pRetro Super vector and
out of these, five seemed to in-
duce a senescent phenotype. Cells
were infected with the vector con-
taining the CRYM shRNA in 4-
plicate and all displayed a similar
phenotype.
nor the biological knockdown eﬃciencies have been tested. Thus, it is critical when
working with the NKi library that at least the latter is confirmed before proceeding to
validate a candidate. For this I analysed the knockdown levels of candidate genes that
purportedly induced an arrest. This was done with a RT PCR reaction for all candidates
and WesternBlot analysis for CRK and FGFR3. Primer sequence design and antibodies
used are described in the Materials and Methods (sections 6.7 and 6.12).
Decreased mRNA levels could be observed in all samples except BID (Figure 13a and
data not shown for BID), although the standard deviation from three biological replicates
with the CRYM and CD68 hairpins was too high to be able to rule out an oﬀ-target eﬀect.
The knockdown of CRK and FGFR3 aroused our interest since both have been pre-
viously reported to be involved in the same signalling pathway, as was shown with the
tyrosine phosphorylation of Crk mediated by the interaction between FGFR1 and the
SH2 domain of Crk [59]. Western blot analysis of whole cell lysates was performed with
cells transduced with either the Crk or the FGFR3 shRNA. There is a clear reduction
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of the FGFR3 protein levels whereas there does not seem to be a reduction in the Crk
levels (Figure 13b).
Figure 13: mRNA and Protein levels of candidate genes after transduction with the candidate
knockdown vectors.a) Relative change of mRNA levels of U2OS cells transduced with the indi-
cated knockdown vectors normalised to U2OS cells transduced with a pRetroSuper-GFP control
vector. ∆∆-RT values. Error bars indicate standard deviation of three separate biological repli-
cates.b)Western Blot analysis of U2OS whole cell lysates transduced with the indicated hairpin
or with the pRS-GFP control vector.
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4.2.3 FGFR3 and CRK
Both FGFR3 and Crk proteins have been shown to have oncogenic potential. Multiple
oncogenic properties of Crk have been extensively described (reviewed in [63]). Mostly,
eﬀects of Crk knockdown in tumours decreases their metastatic and invasiveness potential.
Although, it has been shown in Bcr-Abl positive leukemic k562 cells that the disruption
of the CrkL - Bcr-Abl complex strongly inhibits cell proliferation[64], not many other
proliferation related eﬀects have been shown in the absence of Crk.
Figure 14: FGFR3 is over-expressed in Osteosarcoma
samples. The Oncomine sample database analysis found
a significant over-expression of the FGFR3 protein in Os-
teosarcomas as compared to ten other sarcoma types.
A search with the oncomine
database revealed that FGFR3 is
significantly over-expressed in pri-
mary osteosarcoma tissue sam-
ples (Figure 14). Several groups
have published data that as-
sign tumourigenic properties to
FGFR3[65, 56]. Furthermore,
one group in particular seemed
to be making an association be-
tween osteosarcoma and FGFR3
[66], thus I attempted to repro-
duce some of the published exper-
iments in U2OS cells.
4.2.4 FGFR3 Inhibitor treat-
ment of U2OS cells
Several signaling pathways lead-
ing to and from FGFR3 have
been extensively studied [65]. In
our case, we decided that the
next step was to see whether we
could mimic the cell cycle arrest
seen with the knockdown vector
by chemically inhibiting FGFR3.
We approached this question with two inhibitors which have specifically been shown to
target the FGFR3 receptor in vivo: PD173074 and Masatinib.
The PD173074 compound selectively inhibits the tyrosine kinase domain of all FGFR
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receptors at a concentration of ≈25nM [67, 68]. PD173074 was also shown to be biolog-
ically active and induce FGFR3 dependent apoptosis in myeloma and inhibiting growth
in a mouse xenograft model [57]. The second compound we used is Masatinib another
tyrosine kinase inhibitor which is currently in Phase III clinical study for treatment of
Gastrointestinal stromal tumours [69].
I tested the viability of three diﬀerent osteosarcoma cell lines treated with either one of
the tyrosine kinase inhibitors, however a significant decrease in viability was only reached
at physiologically very high concentrations of >3µM (Data not shown). Thus, treatment
of osteosarcoma cell lines with FGFR3 inhibitor was deemed insuﬃcient to cause cell
cycle arrest or apoptosis in these cell lines. The actual physiological activities of the
FGFR3 inhibitors was not tested to to time and technical constrains.
4.2.5 Subpopulation of FGFR3 positive U2OS cells
The theory that cancers might possess the ability to renew themselves by a subset of
tumour initiating cells (TICs) has grown in credibility in recent years [70]. If the presence
of these cells turn out to be a general mechanism of cancer survival, finding specific cellular
markers could proof to be a powerful new asset in the quest to defeat this disease. Recently
published work demonstrated that in a population of rhabdomyosarcoma cells, roughly
1-3% of the cells were found to express FGFR3. Incidentally, FGFR3+ cells were more
prone to elicit tumour formation when inoculated into nude mice than FGFR3- cells[56].
Figure 15: U2OS cell line has a small population of FGFR3 expressing cells U2OS cells shown
are either untreated, labelled with a IgG isotype antibody or a PE-conjugated FGFR3 antibody
and then analysed by flow cytometry. Populations of FGFR3 expressing cells ranged from 2-9%
in three separate experiments.
One way to explain our previous results (section 4.2.4) was the possibility that in
our screen (section 4.2.1) the U2OS cell originally underwent cell cycle arrest could have
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been a TIC which was dependent on FGFR3 signals to divide. An arrest at a whole cell
population level through the inhibition of FGFR3 either by a knockdown vector or by a
chemical inhibitor would thus be only detectable after a prolonged period of time.
To verify our hypothesis, we attempted to first determine whether as in rhabdomyosar-
coma cells, a small FGFR3+ population could be detected. Fluorescent activated cell
sorting (FACS) analysis, seemed to indeed point to a small subpopulation of FGFR3+
cells residing within a wild-type U2OS population (Figure 15).
Next, I investigated whether the inhibition of FGFR3 would have an eﬀect in the
overall growth of U2OS cells kept in culture for a long term. For this I transduced one
batch of U2OS cells with the FGFR3 shRNA lentiviral vector and kept a second batch
under constant treatment with the PD173074 inhibitor counting the cell numbers every
two days. The expected long term decrease in cell number was not observed after a two
week period and the experiment was thus terminated (data not shown).
Further attempts to verify the eﬀects of the FGFR3 knockdown were inconclusive.
Most importantly, the subpopulation of FGFR3+ cells observed in the FACS experiment,
did not disappear in the FGFR3 shRNA transduced cells.
4.2.6 Mycoplasma infection
Throughout the follow up of CRK and FGFR3 many attempts were done in parallel to
reproduce the eﬀects seen in 4.2.2. Unfortunately this did not turn to be as straightfor-
ward as expected. Results varied greatly after each BrdU / Hoechst / UVa treatment,
with sometimes treated cells surviving the whole treatment altogether. Even after exten-
sive reagent tests where each of the three components were tested separately, no likely
explanation could be found to answer the dilemma. Through literature research, I stum-
bled upon an article on the webpage for the German Collection of Microorganisms and
Cell Cultures which stated that "in the presence of mycoplasmas, BrdU is degraded and
the eukaryotic cells survive even though they do not possess a TK defect"[71]. Indeed it
appears that a combined treatment of BrdU and Light had been previously used to elim-
inate Mycoplasma Orale from cell lines kept in culture[72]. It appears as if mycoplasmas
might insert BrdU into their genomes as well, killing them in the process.
Alas, a quick test with the mycoplasma Kit from R&D systems proved the mycoplasma
hypothesis to be right. It would seem that Mycoplasms insert the BrdU into their own
genomes and the human cell cultures are left with none to insert. If there was a significant
amount of mycoplasmas on the dish, then most of the BrdU would be absorbed in the
process and the cell cultures would not die. on the other hand if there were only few
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mycoplasmas on the dish upon start of the BrdU treatment, then cell cultures would die,
albeit to a much lesser degree as non-mycoplasma infected cells.
After a two week treatment of cell cultures with the MycoKill antibiotic, a new defini-
tive series of tests to confirm the eﬀects seen in Figure 12 was conducted. Again, U2OS
cells were infected with the candidate shRNA lentiviral hairpins and submitted to the
BrdU/Hoechst/UVa killing protocol (Fig 16). Unfortunately, this test done in duplicate
disproved our results, as all cells perished after the treatment. Interestingly, this time
we infected the cells with a hairpin targeting the HDM2 mRNA sequence as a positive
control. Cells with low levels of HDM2 were expected to go into p53 mediated cell cycle
arrest or apoptosis due to elevated p53 levels, and should be readily rescued via the in-
troduction of the Large T antigen. Although more colonies do grow out from the U2OS
cells infected with the pRS-HDM2, there is no obvious diﬀerence between cells infected
with the Large T vector versus untreated cells (Fig 16).
Figure 16: shRNAs found to
not induce a cell cycle arrest in
U2OS cells. U2OS cells infected
with retroviral vectors containing
an shRNA targeting the indi-
cated genes and submitted to a
BrdU Hoechst UVa treatment.
After a 48 hour recovery pe-
riod, cells were either infected
with the pLKO.2-CMV-Large
T vector (upper panel) or left
untreated (middle panel). Cells
were stained with crystal violet
after a 20 day recovery period.
Cells were infected with a pRS-
GFP vector as a negative control
(lower panel) and submitted to
the same treatment.
Given that most of the follow up experiments on CRK and FGFR3 had been started
already we decided to carry on albeit the discouraging results.
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5 Discussion
Every new technology is bound to meet setbacks before being fully implementable. As ex-
pected at the beginning of my yearlong project, the setting up of a new screening method
from scratch would prove challenging. Recently the group of Wei Gu described the pre-
viously uncharacterised protein ULF to be a ubiquitin ligase for ARF[73]. Interestingly,
knockdown of ULF caused the stabilisation of ARF in primary human cells triggering
ARF-dependant p53 cell cycle arrest. The discovery of ULF showed that unknown in-
hibitors of p53 activators remain to be found and that the cell actively uses this kind of
signalling to counteract environmental insults. Thus, during my thesis I have successfully
laid down the foundation for what could be a very promising tool. The eﬃcacy of each
of the four steps in our approach can hitherto be tested independently using other model
cell lines.
5.1 Test Screen - Controls
Admittedly, there were some flaws in the first test screen I performed in U2OS cells
(see section: 4.2.1). This made it impossible to assess with a strong confidence whether
actual hits were found. Nonetheless, I am confident that there is a great potential for this
screening method to positively detect further novel inhibitors of the pathways leading to
cell cycle arrest. Given more time I would have repeated the U2OS screen taking into
account several of the mistakes from the test screen and modifying these parameters
accordingly.
First of all, the lack of appropriate positive and negative controls made it impossible
to adequately determine the signal to noise ratio of our screen. A good positive control
could give us the definitive proof that our approach works, however given our mishap with
HDM2 (section 4.2.6) it will prove challenging to find an appropriate control. Instead
we propose an alternative method by slightly altering the screen so as to include a test
positive control within the screen itself. The idea being to follow the protocol as-is up to
the Large T infection. At which point, instead of picking individual colonies, one would
count all present colonies and then pool them together without ever passaging them.
The genomic DNA can then be isolated from the pool of colonies, and a PCR reaction
is performed to amplify all hairpins present. The PCR products can then be ligated
into an empty pRetroSuper vector to create a new library NKi 2.0 theoretically enriched
with positive hits. Whether this is true can be easily shown by performing a second
screen with the new NKi 2.0 library. We hypothesise that if the BrdU killing protocol
can indeed selectively kill dividing cells, then one would expect a much larger number
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of colonies forming in a screen of the NKi 2.0 than with the original NKi 1.0 library. If
this hypothesis holds, then the protocol is followed as described above (Section 4.2.1) to
identify individual hairpin candidates.
As to the negative control, with our conditions it was impossible to determine the
number of background colonies in untreated cells during our screen. We have observed
a very low background level (1-2 colonies per dish) in independent experiments (Figures
10b and 16 and data not shown), however it is very important to assess this in parallel to
the pRS-NKi infected cells. During my time at the lab, I did indeed start a series of new
screens in which I had adjusted for this parameter. I attempted to repeat the screen in
several occasions adjusting for this parameter by infecting a total of 6.0×107 cells with the
NKI virus and a total of 2.0×107 cells with the control pRS-GFP vector. Unfortunately
these attempts had to be stopped once the mycoplasma infection previously described
was identified (section: 4.2.6).
5.2 General Improvements
Overall, with the experience I have gained, I have recognised several potential bottlenecks
and given the time would make the following changes when performing a screen either
on the U2OS cell line or on another cell system. Again, I cannot emphasise enough that
the most important method is the killing protocol, however once this hurdle is overcome,
and an appropriate cell line has been found there are certain changes which would make
the screening method more robust.
5.2.1 Stable inducible expression of the LargeT antigen
We chose to deliver the Large T antigen into non-dividing cells by Lentiviral infection.
It is the most reliable if not the only method for delivering a foreign DNA sequence into
a non-dividing cell’s DNA. When following our experimental conditions at the time of
the LargeT - dependent cell cycle induction, cells have been exposed to several stresses
namely: Infection with a retroviral vector, induced cell cycle arrest, BrdU and subse-
quent UVa treatment. Furthermore, if the cell has been brought to the cell cycle arrest
stadium in a p53 dependant manner, its DNA-repair capabilities might be compromised
and insertion of the lentiviral DNA might produce irreparable damage. Thus we believe
that an inducible expression system would increase the signal to noise ratio of our screen.
We propose that once the appropriate cell line is found, the cell line can be modified to
stably contain and express the Large T antigen under the control of a Tet-On tetracycline
inducible promoter [74]. This way the LargeT expression can be activated from within
the cell without tampering further with the genomic make up.
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5.2.2 Alternative Screens
Of particular interest would be to attempt the screening method on diﬀerent cell lines,
specifically applying the method on primary tumour cells or a primary non-tumorigenic
cell line. These cell lines are of much closer genetic resemblance to human and thus serve
as a better model. Thus, the results arising from such a screen would be of a greater
clinical value. As I have shown, during the first half of my thesis I have attempted to
establish some of the screening steps with diﬀerent cell lines (section 4.1.1). Several
setbacks were encountered with each of the cell lines however I am confident that given
more time, an appropriate cell system will be found. Although all steps in the screen are
important in themselves, the most critical step remains the BrdU/Hoechst/UVa killing
protocol. In order to reduce background it is of upmost importance to achieve a killing
degree comparable to that achieved in the U2OS or HeLa cell lines (Figures 9 and 16).
5.2.3 Variations of the screen
Cells lines which are deemed suitable for the BrdU killing procedure can be screened
in diﬀerent ways. For example newer, larger, sequence and functionally verified shRNA
libraries like the ones created by The RNAi Consortium (TRC) can be used.
Furthermore, in addition to performing the screen with the Large T antigen as a means
to induce arrested cells back into cycle, the screening method could also be expanded to
use other known oncoproteins. There is a myriad of proteins which would come into
question, a good candidate would be the human papilloma virus (HPV) E7 oncoprotein
which has been shown to be required for HeLa cell proliferation in the presence of the
HPV E6/E7 inhibitor protein E2 in a pRB dependant manner [75]. Thus, a further
application of the screening method can be conceived that uses the E7 protein instead of
the Large T antigen to bring cells back into cycle to gain further insight into the pathways
which lead to cellular senescence.
5.3 Candidate Follow up
The eﬀect of FGFR3 knockdown on cell proliferation is definitely an area of interest (see
[65, 56, 66] or Figure14), none of these studies have provided insight into the mechanistic
properties of the observed oncogenic potential of FGFGR3, thus a link to the p53 pathway
can neither be assumed nor entirely ruled out. Although the hit could not be confirmed
in our hands it is still plausible that we have found it as a positive hit with our screen.
There exists a vague possibility that we knocked down FGFR3 in the subpopulation of
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FGFR3 expressing cells (Figure 15) and that this caused cell cycle arrest. It would be
interest to try to isolate these FGFR3 cells through flow cytometry and see if knockdown
of FGFR3 in these cells will induce the expected cell cycle arrest.
Looking at the RT-PCR data, we decided to discard the rest of the candidates as
background noise as the shRNA vectors seem to induce no visible knockdown of their
target genes. Although given the variance in some of the samples (i.e. CRYM in Figure
13a) it would also be advisable to measure the mRNA levels again with diﬀerent RT PCR
primers .
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6 Materials and Methods
6.1 Cell lines
IMR90 (ATCC ID: CCL-186) fibroblasts cells are derived from a human embryonic lung
of a 16 week female foetus. The cells were taken in culture at passage 13. Attempts to
immortalise them with a hTERT lentiviral construct were unsuccessful.
U2OS (ATCC ID: HTB-96) osteosarcoma cells are derived from a sarcoma of the tibia of
a 15 year old girl. These cells are p53 and pRB wild-type. No known viral proteins have
been detected.
HeLa (ATCC ID: CCL-2) cells are derived from a 31 year old female and are widely used
in research. HeLa cells have been reported to contain HPV-18 sequences.
MCF-10a (ATCC ID: CRL-10317) cells are derived from from a non-tumorigenic epithelial
cell line of a 36 year old female. The cells exhibit three dimensional growth in collagen.
No known viral proteins have been detected.
6.2 Vectors
6.3 Primers
6.3.1 Large T Cloning
Forward primer with AgeI site: GATCCCACCGGTACCATGGATAAAGTTTTAA Re-
verse primer with EcoRI site: GATCCGAATTCTTATGTTTCAGGTTCAGG
The primers were designed to amplify the LargeT sequence from a functional pBABE-
hygro-CMV-LargeT. A PCR was performed using 10ng of the pBABE-hygro vector,
the product was then digested with EcoRI/AgeI restriction enzymes and ligated into
a EcoRI/AgeI digested pLKO.2-CMV-Puro vector. XL10 Gold E.Coli cells were trans-
formed with the ligation product and grown on LB Amp- selective plates. Plasmid DNA
was then isolated from growing E.Coli colonies. Plasmids were sequence verified and
functional expression of the Large T antigen was verified through Western Blot analysis.
6.4 BigDye© Sequencing reaction
The BigDye sequencing reaction was done with the Qiagen BigDye© Terminator v3.1
sequencing kit. It’s based on the linear amplification of a DNA sequence. Per standard
sequencing reaction, 50-100ng PCR product or 250ng plasmid DNA were mixed with 1µl
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5x sequencing buﬀer, 1µl primer (use only one primer per reaction), and the 0.5µl of the
BigDyev3.1 master mix. The mix was filled up to 10µl with MQ and incubated on a
thermocycler instrument with the following program: 96◦C for 1’, 96◦C for 10”, 50◦C for
5”, 60◦C for 4’ repeat 25 times.
To purify the LAMP product from non-incorporated nucleotides, 10 µl MQ were
added, the mix was eluted over a G50 Sephadex minicolumn at 2200g for 2 minutes. 2µl
of the purified product were mixed with 10µl Formaldehyde.
6.5 Virus Production in 6-well plate format
HBS
CaCl2
6.5.1 Virus production
Final concentrations of DNA are not important for the transfection. The quantities
mentioned here are for transfections of 1 well of 70-80% confluent 293T producer cells on
a 6-Well plate. 2.3 µg δR8.91, 0..3µg VSVG, 0.2µg CMV-GFP were mixed in one tube
and 0.4µg of the lentiviral vector of interest were added to the mix. Then 158µl 1X HBS
pH6.5 was pipetted to the DNA mix, and as quickly as possible 8.33µl CaCl2 are added
to the solution. The HBS/DNA/CaCl2 mix was vortexed immediately. 293T packaging
cells were plated for no longer than 12 hours prior to the transfection. The transfection
mix was pipetted drop-wise directly onto the medium. After an incubation of ≈24 hours
the 293T cells are checked under the fluorescent microscope, and I proceeded to the next
step only when 90% of cells were GFP positive (green).
The DMEM was changed with 1.5mL fresh DMEM. DMEM supernatant containing
the viral particles was harvested in roughly 12-14 hour intervals, but never more than
three times. To remove remaining 293T cells from the medium, the supernatant was
either spun down at full speed for 5 min, or filtered through a 45µM sterile syringe filter.
6.5.2 Test infection
To determine virus titre, harvested supernatant was applied directly to target cells in a
dilution series. For this a master mix of 10X polybrene and the viral harvest filled up
to 1ml with DMEM was prepared. Infection eﬃciency was validated either by selecting
with an antibiotic or by fluorescence microscopy if a GFP tag is present in the vector of
interest.
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6.6 Test screen in U2OS cells
To achieve an infection rate with a high confidence of hitting all vectors at least once
we would have to infect 4.8×106 cells. For an even higher confidence we decided to
infect three times as many cells thus we infected 13.5×106 cells. As a negative control
I infected 2.5×106 cells with a pRetroSuper vector containing an antisense GFP shRNA
hairpin. The BrdU (10µM final concentration) treatment was started after selecting for
48 hours on puromycin and was left on for 72 hours. To avoid overgrowth, and resulting
contact inhibition dependent growth arrest, the dishes were split once they reached a
70% confluency. The cells were then treated with Hoechst #33158 dye (10µg/ml final
concentration) for 3 hours and the cells were then irradiated from the bottom with a
230V, 5 Watt E27 UV lamp for 15 minutes after which fresh medium was added. The
cells were infected with the plKO.2-CMV-Large T virus 48 hours after UVa irradiation, a
control dish with untreated U2OS cells was infected to assess virus titre. The dishes were
kept in culture for three weeks, changing the medium every 3-4 days. The dishes were
washed once with PBS after which 7mL PBS was added per dish. A total of 100 colonies
were picked with a 200 µl Gilson pipette and transferred to a 96-well plate containing
100µl of trypsin and incubated at 37◦C for 4 minutes. The ∼150µl were then transferred
to 48 well plates containing 700µl DMEM. Cells were allowed to grow to a confluent state
at which point they were transferred to 6-well plates. Genomic DNA was isolated from
confluent 6-well wells using the Promega Wizard Genomic DNA Purification Kit. A PCR
using the fwd and rev primers was performed to amplify the inserted hairpin from the
genomic DNA. The 200bp PCR products were sequenced to establish the identity of the
inserted hairpins.
6.7 Western Blot
4x SDS sample buﬀer 320 mM Tris-HCl pH 6.8 40% (v/v) Glycerol 0.008g bromphenol
blue 8% SDS (stock is 20%) 20% (v/v) beta-mercapto-ethanol (add freshly) Add all
reagents to make 500 ml total but beta-mercaptoethanol Then final volume = 400ml
0.2% (w/v) iBlock solution 0.2g/100ml PBS iBlock powder Heat to 60◦C in the
microwave Stir until granules are dissolved Add Tween 20 (0.1% v/v)
Running Buﬀer Blotting Buﬀer ECL
6.7.1 Harvesting
Cells were infected or transfected with a plasmid containing our gene of interest (GOI).
Cells were harvested after suﬃcient time for expression (usually two to three days). First
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the cells were washed once with PBS and then 200-300µl 4x sample buﬀer were added.
The cells were scraped from the dish with a rubber policeman and transfer into a 1.5ml
eppendorf tube.The samples were boiled at 95◦C for 5-30 min, depending on viscocity.
6.7.2 Running
After the samples have cooled down, 5-25µl (up to 20µg/ lane) were loaded on a pre-
poured polyacrylamide gel. 4µl of the pre-stained marker were used each time. The
current was set up to 200V for as long as required in running buﬀer (until front had
reached the bottom of the gel). After the run,50% of the running buﬀer were always
poured back into the original container and the rest was discarded.
6.7.3 Blotting
The gel was transferred into blotting buﬀer trying to always keep the membrane wet. Do
not touch the membrane without gloves. To blot, a PVDF membrane was cut to the same
size as the polyacrylamide gel. The membrane is activated by washing 1x 5min. in 100%
ethanol. The membrane was placed on top of the gel and pressed together with the help
of filter paper and sponges. The blotting reaction was run at 400mAmp keeping in mind
that proteins are negatively charged and will mobilize in the direction of the cathode.
6.7.4 Antibody incubation and exposure
After the transfer, the protein ladder should be visible on the PVDF membrane. The
membrane was incubated for 30min in BSA or iBlock blocking solution to avoid back-
ground detection of the antibodies and later was incubated at 4◦C overnight with the
appropriate primary antibody. The next day, the membrane is washed 3x 10min. with
PBS-Tween and then incubated for approx. one hour with the corresponding PE conju-
gated secondary antibody. After incubation the membrane was washed 3x 5min. with
PBS-Tween, then dipped 3x into a 1:1 ECL mix. Proceed to develop membrane.
6.8 Transformation of E.Coli Competent cells
For this, the E. coli strain XL10 Gold( galE galK galU+) is used. It has a doubling time
of approx. 50 min. 50 µl of competent E. coli cells were thawed on ice and gently mixed
with 5 µl of Ligation mix. The suspension was incubated for 10 minutes on ice. The cells
are then heat shocked for 30 seconds at 42◦C on a water bath and quickly put back on ice
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for 2 minutes. 250 µl of SOC medium are added and the transformed cells are incubated
at 37◦C, 250rpm for 30 minutes. Cells were plated and incubated on selective lysogeny
broth (LB) plates at 37◦C over night.
6.9 DNA isolation
6.9.1 Minipreps
The day after transformations, single colonies were picked and grown over night in 4ml LB
medium containing the Ampicilin antibiotic at 37 ◦C. Spin down 3 minutes at 6000 rpm
the next day. The pelleted bacteria was resuspended in 250 µl buﬀer P1 and transferred
to an Eppendorf tube. 250 µl buﬀer P2 are added and the tube was mixed thoroughly by
inverting 4 - 6 times. 350 µl buﬀer N3 were added and mixed immediately and thoroughly
by inverting the tube 4 - 6 times. The mix was centrifuged for 10 minutes at 13,200 rpm
in a table-top micro-centrifuge. The supernatants were decanted onto the QIAprep spin
column which was then centrifuged for 30 seconds. The QIAprep spin column was then
washed once with 0.5 ml buﬀer PB and once with 0.75ml buﬀer PE. The QIAprep column
was then placed in a clean 1.5 ml Eppendorf tube and to elute DNA, 50 µl water was
added to the center of each QIAprep spin column.
6.9.2 Extract and purify DNA from standard agarose gels in TAE buﬀer:
For this, we used the QIAquick Gel Extraction Kit. Up to 400 mg agarose can be
processed per spin column. The DNA fragments were excised from the agarose gel with
a sterile, sharp scalpel. The gel slice was weighed in a colourless tube and 3 volumes
of buﬀer QG were added per 1 volume of gel. The mix was incubated at 50 ◦C for 10
until the gel slice had completely dissolved. One gel volume of isopropanol was added
to the sample and the mix was placed in a QIAquick spin column. The sample was
applied to the QIAquick column, and centrifuged for 1 minute. After discarding the flow-
through, 0.5 ml of Buﬀer QG were added to the QIAquick column and centrifuged for 1
minute. 0.75 ml of Buﬀer PE were added to the QIAquick column to wash and then it
was centrifuged two times for 1 minute. 50 µl of water were added to the center of the
QIAquick membrane and the column was centrifuged for 1 min.
6.9.3 Maxipreps
A single colony from a freshly streaked selective plate was picked with a pipette tip and
200ml LB containing the appropriate selective antibiotic were inoculated and incubated
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for approx. 16 hours with vigorous shaking at 37◦C. The bacterial cells were harvested by
centrifugation at 6000x g for 15 min at 4◦C. The bacterial pellet was resuspended in 10
ml Buﬀer P1 until no flocks are left. 10 ml Buﬀer P2 were added and mixed thoroughly
by vigorously inverting the sealed tube 4-6 times, and incubated at room temperature
for 5 minutes. 10 ml chilled Buﬀer P3 were added to the lysate, and mixed immediately
and thoroughly by vigorously inverting 4-6 times. The lysate was poured into the barrel
of the QIAfilter Cartridge and incubated at room temperature for 10 min. The plunger
was gently inserted into the QIAfilter Maxi Cartridge to filter the cell lysate into a 50 ml
tube. 2.5 ml Buﬀer ER were added to the filtered lysate, and it was mixed by inverting
the tube approximately 10 times and incubate on ice for 30 min. A QIAGEN-tip 500
by was in the meantime equilibrated by applying 10 ml Buﬀer QBT, thus allowing the
column to empty by gravity flow. The filtered lysate was then added to the QIAGEN-tip
and allow it to enter the resin by gravity flow. After the lysate had flowed trough the
QIAGEN-tip was washed 2x with 30 ml Buﬀer QC. The DNA is eluted with 15 ml Buﬀer
QN and collected in a tube pretreated with isopropanol. To precipitate the DNA 10.5ml
(0.7 volumes) room-temperature isopropanol were added to the eluted DNA mixing and
centrifuging immediately at 15,000 x g for 30 min at 4◦C after which the supernatant
was carefully decanted. The DNA pellet was washed with 5 ml of endotoxin-free room
temperature 70% ethanol and centrifuged at > 15,000 x g for 10 min. Decant supernatant.
The pellet was resuspended in 180 µl ddH2O.
6.10 Dephosphorylation
20 µl of digested (and in this case blunted) DNA was mixed with 3 µl of 10x CIAP buﬀer
and 3 µl of CIAP and ddH2O was added to a final volume of 30 µl. This reaction mix
was incubated at 37 ◦C for 30 min. Afterwards, the enzyme was inactivated by heating to
65◦C for 15 min and the DNA was purified for ligation using a Qiagen PCR purification
kit according to the manufacturer’s protocol.
6.11 Ligation
For ligation 2.5 µl of 2x ligation buﬀer is mixed with appropriate amounts of vector and
insert DNA and 0.5 µl T4 DNA ligase (3 u/µl, Promega), giving a final volume of 10 µl.
After incubation for 3 h at RT or overnight at 16◦C, this mix is used for transformation.
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6.12 Real-Time PCR
6.12.1 Primers
FGFR3
Forward primer:
GTCGGCGCCTTTCGAGCAGT
Reverse primer:
CATGCCGGGGAGTGGCTGTG
Product size: 211
CRK
Forward primer:
TCTCAGGCAGTGCAAATCAC
Reverse primer:
CGGTGCATGATTACTTCACG
Product size: 162
BID
Forward primer:
AGCTGCTGCAGGCCTACCCT
Reverse primer:
AAGGACGGCGTGTGACTGGC Product size: 100bp
CRYM
Forward primer:
GGATCGCGGTGCGGAGACTG
Reverse primer:
AGGCGGGATGAGGAGGCTGG
Product size: 122
CD68
Forward primer:
GGTGGAGGAGAGGCCTGGGG
Reverse primer:
GCTGCGTGGGGGAAGGACAC
Product size: 203 bp
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6.12.2 Isolation of whole cell RNA
Isolation of RNA was performed with the RNeasy Mini kit from Qiagen. Cells were
infected with the virus containing the desired knockdown vector, and RNA was isolated 48
hours post Puromycin selection. Cells were lysed by adding 350µl buﬀer RLT directly to
the 6-well plate. Cell lysates were then transferred to a 1.5ml eppendorf tube containing
200µl RNAse free H2O and 350µl Buﬀer RLT. The lysate was then pipetted directly
into a QIAshredder spin column placed in a 2ml collection tube and centrifuged for 2
min at full speed. 900µl of 70% ethanol was added to the homogenised lysate and the
mix was transferred to a RNeasy spin column and centrifuged for 15s at 8,000g. The
column membrane is washed with 700µl of Buﬀer RW1 then twice with 500µl Buﬀer
RPE. The RNA was eluted in 14µl RNAse free H2O. RNA concentration was determined
by measuring 2µl on the NanoDrop™ machine.
6.12.3 Eliminating DNA from RNA sample
DNA was removed with the TURBO DNA-free™ kit from Applied Biosystems. First
1.5µl 10x TURBO DNase Buﬀer and 1µl TURBO DNase were added to the RNA and
the sample was incubated at 37◦C for 30 minutes. To inactivate the reaction 1.5µl DNase
inactivation reagent were added to the solution and incubated for 2 minutes at room tem-
perature. The sludge was then centrifuged at 10,000 g for 1.5 minutes and the supernatant
was transferred to a fresh tube.
6.12.4 Reverse Transcription cDNA synthesis
The cDNA synthesis reaction was performed with the RevertAid™ M-MuLV Reverse
Transcriptase kit from Fermentas optimised of use in a two-step RT-PCR. A total of
1µl of template RNA was used per reaction and mixed with 0.2µg of random hexamer
primers. The reagents were then added in the following order, 4µl 5x reaction buﬀer,
0.5µl RiboLock™ RNase Inhibitor, 2µl of a 10mM dNTP mix, and finally 1µl of the
RevertAID™ M-MuLV Reverse Transcriptase. The total volume of the mix should be
20µl.The RT mix is incubated at 20◦C for 10 minutes followed by 30 minutes at 50◦C and
later filled to 100µl with H2O. A negative control reaction without the M-MuLV Reverse
Transcriptase was performed for every sample.
6.12.5 PCR
The PCR reaction was performed with the iQ™ SYBR® Green supermix. A master
mix is made by pipetting 5µl of the BioRad Supermix, 0.25µl of a forward and reverse
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primer mix and 3.75µl H2O per reaction. A total of 1µl of the diluted cDNA is analysed
per reaction. All reactions were done in triplicate, except for the negative control (from
section 6.12.4). Analysis was done with a BioRad RT machine.
6.13 FACS
The FACS experiment was performed with a phycoerythrin conjugated FGFR3 antibody
(PE-FGFR3ab) and a PE-IgG antibody as a negative control. The staining was performed
in a staining buﬀer containing 0.5% BSA 1% FBS and 0.1% NaN3. U2OS cells were
grown to 50% confluency on a 100mm dish. To detach, cells were incubated in 3ml PBS-
EDTA at 37◦C for 10-15 min. until cells looked rounded up and detached under the
light microscope. Cells were mixed thoroughly by pipetting up and down, and a 200µL
aliquot was used to count the cells the rest were then spinned down at 500g for 3 min,
and then washed three times in the staining buﬀer. Cells were then diluted in PBS to
a concentration of 4000 Cells/µl. 10,000 cells or 25µl were incubated in 10 µl of the
respective antibody at 4◦°C in the dark for 45 minutes. After the staining cells were then
washed two times in staining buﬀer and finally dissolved in 400µl for measurement.
6.14 Sensitivity of osteosarcoma cells for FGFR3 inhibitors.
Sensitivity of Osteosarcoma was tested with PD173074 (Mw 523.67 g/mol) and Masatinib
(Mw 498.65 g/mol) at diﬀerent concentrations ranging from 0-20,000 nM. Both inhibitors
were dissolved in DMSO as indicated by the supplier. The osteosarcoma cell lines tested
were U2OS, SaOS and MG63. ≈5,000 cells were plated per well on a 96-well format,
and the inhibitors were administered for 72 hours. Cell viability was measured with the
Cell-Titre Glo Luminescent Cell Viability Assay kit from Promega. All measurements
were performed in triplicate.
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